No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... October 4, 2019 Black In Cancer – That Cancer Conversation October 8, 2021 Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven... February 10, 2021 Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... April 13, 2020 Load more HOT NEWS Cancer Research UK’s charity Christmas cards now available Approximately 1 Million of New Maternal Orphans Due to Cancer in... EMA Recommends Granting a Marketing Authorisation for Generic Eribulin ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ
